Nordic Bioscience

Registration is now open to our next webinar (co-hosted with The Extracellular Matrix Pharmacology Congress)! This time, the focus is on pulmonary fibrosis in a preclinical context, with a focus on the mechanisms driving lung fibrosis and the role of machine learning in patient stratification, especially in COPD and other fibrotic pulmonary disorders. #DrugDevelopment #PrecisionMedicine #COPD #PulmonaryFibrosis

We're excited to share findings from our latest exploratory study published in #OACopen investigating how local tissue damage in joints impacts systemic biomarker levels. Specifically focusing on C3M, a marker of type III collagen degradation, we explored its potential role in tracking soft tissue damage and remodeling in patients undergoing joint replacement revision surgeries. Read our key findings below: ✔️ Patients who underwent revision surgery exhibited a significant, yet temporary, increase in C3M levels, suggesting active tissue degradation and remodeling. These levels normalized within 2-3 months, indicating the biomarker's sensitivity to acute tissue damage and healing processes. ✔️ Our results indicate that even damage in a single joint can influence systemic biomarkers, reinforcing the relevance of C3M in monitoring soft tissue turnover and inflammation in osteoarthritis. ✔️ We add to the growing body of evidence supporting the use of serological biomarkers as surrogate endpoints in osteoarthritis trials, with potential to accelerate the development of effective therapeutic strategies. 📰 The full paper can be found here: https://lnkd.in/dwSFnQnC Big thanks to the team and our collaborators, as always! #Osteoarthritis #TissueRemodeling #Biomarkers #JointReplacement #MedicalResearch #Orthopedics #ClinicalTrials

Our CPa9-HNE blood-based biomarker assay has received a Letter of Support from the FDA. CPa9-HNE, also known as the Nordic Serum Calprotectin biomarker, measures activated neutrophils and is now recommended for inclusion in studies on inflammatory bowel disease (IBD). 📺 Watch the below video animation to learn how CPa9-HNE may enhance your study program! 🔗 Reach out to Elijah Aighobahi or Joachim H. Mortensen if you wish to learn more! Martin Pehrsson, Ph.D Marta S. Alexdóttir Thomai Tsapanou-Katranara #IBD #DrugDevelopment #Colitis #CrohnsDisease

Great Momentum at #UEGWeek 2024! Our Nordic Bioscience IBD team have presented 2 oral presentations and 2 more to go today. It was amazing to see the talk on the Mistakes in IBD biomarkers and to understand that biomarkers from the same protein can measure different biological processes. A fragment of serum calprotectin, CPa9-HNE can exclusively quantify neutrophil activity in contrast to the full Calprotectin protein, which quantifies both active and non-active neutrophils. Joachim H. Mortensen highlighted the need to go beyond inflammation and CRP, emphasizing that both neutrophil activation and mucosal damage are equally important in assessing and monitoring disease activity in #IBD. Thomai Tsapanou-Katranara nicely presented promising data on the Nordic C3-HNE, a biomarker of type III collagen derived from human neutrophil elastase. Showing potential for early detection of mucosal damage and acute gut inflammation in pre-clinical models. Looking forward to today’s exciting oral presentations from Joachim and Martin Pehrsson, Ph.D on the relevance of ECM collagen remodeling biomarkers reflecting mucosal damage and intestinal fibrosis in IBD! If you're attending UEG Week, feel free to join these sessions: 🔹 Title: PRO-C11 AND PRO-C16 ARE MARKERS OF INTESTINAL FIBROSIS AND ARE ASSOCIATED WITH MRE-CONFIRMED INTESTINAL STRICTURES – RESULTS FROM THE IMAGEKIDS STUDY 📅 Time: 10:00 - 10:12 (CET) 🔹 Session: IBD: Diagnosis and Monitoring 🎤 Presenter: Dr. Joachim Høg Mortensen 🔹 Title: ACTIVATED MACROPHAGE-CONDITIONED MEDIA INDUCES FIBROGENESIS IN A GASTROINTESTINAL SCAR-IN-A-JAR MODEL THAT IS QUANTIFIABLE WITH SEROLOGICAL BIOMARKERS OF COLLAGEN FORMATION 📅 Time: 11:42 - 11:48 (CET) 🔹 Session: Identifying Drug Targets in IBD: Part 2 🎤 Presenter: Dr. Martin Pehrsson Marta S. Alexdóttir Joachim H. Mortensen Martin Pehrsson, Ph.DThomai Tsapanou-Katranara #UEGWeek2024 #IBD #Biomarkers #MucosalHealing #IntestinalFibrosis

We are going to #UEGWeek! Our gastroenterology team will have a strong presence at UEG Week 2024 in Vienna, with four oral presentations and two poster presentations showcasing our latest research in gastrointestinal health. In addition, we will be happy to discuss how our CPa9-HNE Serum Calprotectin biomarker can contribute to IBD programs, which has now received a Letter of Support for its role in monitoring disease and neutrophil activity in Inflammatory Bowel Disease (IBD). 📩 Reach out to Elijah Aighobahi connect or Joachim H. Mortensen if you wish to learn more! Martin Pehrsson, Ph.D Marta S. Alexdóttir Thomai Tsapanou-Katranara #IBD #DrugDevelopment #Colitis #IngestTheBest

We are pleased to share that our CPa9-HNE blood-based biomarker assay has received a Letter of Support from the FDA. CPa9-HNE, also known as the Nordic Serum Calprotectin biomarker, measures activated neutrophils and is now recommended for inclusion in studies on inflammatory bowel disease (IBD). CPa9-HNE may enhance clinical trials by identifying patients with moderate to severe active ulcerative colitis or Crohn’s disease, potentially reducing the need for unnecessary endoscopies. The FDA encourages formal qualification of CPa9-HNE as an enrichment biomarker through analytical validation and data sharing across clinical trials to advance its development as a drug development tool. ➡️ Read the full news and the Letter of Support on the link below: https://lnkd.in/e_7TSxr9 #FDA #IBD #LetterOfSupport #DrugDevelopment #Neutrophils #CPa9HNE

September is pulmonary fibrosis (PF) awareness month—a progressive lung disease that affects over 200,000 people in the United States alone. PF causes scarring of lung tissue, leading to severe breathing difficulties and reduced quality of life. At Nordic Bioscience, we are dedicated to advancing the development of biomarkers that provide deeper insights into disease progression in pulmonary fibrosis. Together with our collaborators, we contributed to the Lancet publication: “Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.” This research represents a step forward in identifying endotypes that can help improve the monitoring of the disease and guided therapy, ultimately enhancing patient care. We hope our findings encourage continued research and collaboration, working together to make a lasting impact! 📰 Publication: https://lnkd.in/dgYZG5mT #pulmonaryfibrosis #pulmonary #IPF #fibrosis #PulmonaryFibrosisMonth Diana Julie Leeming Filipa Simões Jannie M. B. Sand Sarah Rønnow Annika Hummersgaard Hansen, PhD

🌟 What an incredible week it's been! 🌟 I started last week at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston, where Grace Robertson and her team put together yet another fantastic event! I had the privilege of connecting with so many brilliant minds from biotech and pharma, discussing how our PRO-C3 biomarker, the first-ever tumor fibrosis biomarker to receive a letter of support from the FDA as a clinical trial enrichment tool, can help identify optimal responders for therapies in development across solid tumor types. The positive reception to our science was overwhelming, and I’m beyond excited to continue these conversations with my team at Nordic Bioscience Right after Boston, I had the pleasure of heading to #ESMO in Barcelona alongside Nicholas Willumsen, who is leading our oncology efforts. If you're interested in potentially doubling the response rates of your oncology treatments with just a single biomarker measured in serum or plasma, I highly recommend reaching out to Nicholas or myself. Even better - if you know anyone working in this space, please tag them in the comments below so we can get connected. It’s been a whirlwind week of inspiration, collaboration, and new opportunities, and I can’t wait to see what’s next! #biomarkers #oncology #solidtumors #biotech #pharma #PROC3 #NordicBioscience #ADC #IO #CPI Morten Asser Karsdal Claus S. von Arenstorff Sarah Rønnow Elijah Aighobahi Signe Hausgaard Larsen Daniel Gabor Diana Julie Leeming Federica Genovese Joachim H. Mortensen Jannie M. B. Sand Signe Holm Nielsen, PhD Christian Thudium Mayuur Bajaj

Happy to be attending the ERS conference in Vienna! I love this fantastic possibility to connect with leading experts and discover the latest research. I am here with my colleagues, who are presenting our latest biomarker data. If you are here too, reach out if you would like to connect and share ideas. #ERS #Biomarker #RespiratoryScience #NordicBioscience

We’re thrilled to announce that we’ll be presenting new data #ERS in Vienna (Sep 7-11)! We will showcase findings from our SiaJ (Scar in a Jar) model where we’ve tested treprostinil. Our research demonstrates its significant impact on fibroblast activity, a critical factor in developing effective treatments for Idiopathic Pulmonary Fibrosis (IPF).   Understanding fibroblast behavior is crucial in IPF progression, and our results could offer valuable insights for future therapeutic applications. We believe this work has great potential to further enhance the success for future drug development.   If you're attending ERS, reach out to Sarah Rønnow to learn more and explore potential collaborations. Diana Julie Leeming Filipa Simões Annika Hummersgaard Hansen, PhD #drugdevelopment #IPF #lung #clinicaltrials #ERS2024